Abstract: A display apparatus, an adjustment method and a formation method are provided in the present disclosure. The adjustment method includes recording a voltage value inputted to the first power signal line as a value A, where the value A is an actual voltage value of the first power signal line when the display panel is at the first target brightness level and the drive transistor operates in a saturation region; inputting the value A to the first power signal line in the display panel, reading a first actual data voltage value on a data line in the display panel at this point, and re-finding a first actual grayscale value corresponding to the first actual data voltage value from the gamma curve; and programming the value A, the first actual data voltage value and the first actual grayscale value corresponding to the value A into the drive chip.

Abstract: The invention discloses a low power consumption and high precision resistance-free CMOS reference voltage source circuit, which includes a, a positive temperature coefficient voltage generation circuit and a starting circuit. The self-bias current source circuit uses two NMOS tubes with different threshold voltages in the subthreshold region to form a stack structure, which generates the bias current and negative temperature coefficient voltage on the order of nanoampere. The positive temperature coefficient voltage generation circuit uses PMOS differential to generate positive temperature coefficient voltage for the structure and performs first-order curvature compensation for negative temperature coefficient voltage.

Abstract: In one aspect, the present disclosure provides a method of treating, preventing, and/or ameliorating premature ovarian failure (POF) in a subject in need thereof, wherein the subject is a female cancer patient being administered at least one chemotherapeutic drug, the method comprising administering to the subject at least one c-Jun N-terminal Kinase (JNK) inhibitor. In certain embodiments, the JNK inhibitor is SP600125. In another aspect, the present disclosure provides a pharmaceutical composition comprising a JNK inhibitor.

Abstract: The present invention relates generally to a three-dimensional cell and tissue culture system for the female reproductive tract. In particular provided herein the system includes individual female reproductive cultures in a dynamic microfluidic setting or integrated using a microfluidic microphysiologic system. In some embodiments, the present invention provides ex-vivo female reproductive tract integration in a three dimensional (3D) microphysiologic system.

Abstract: The present invention relates generally to a three-dimensional cell and tissue culture system for the female reproductive tract. In particular provided herein the system includes individual female reproductive cultures in a dynamic microfluidic setting or integrated using a microfluidic microphysiologic system. In some embodiments, the present invention provides ex-vivo female reproductive tract integration in a three dimensional (3D) microphysiologic system.

Abstract: The present invention relates generally to a three-dimensional cell and tissue culture system for the female reproductive tract. In particular provided herein the system includes individual female reproductive cultures in a dynamic microfluidic setting or integrated using a microfluidic microphysiologic system. In some embodiments, the present invention provides ex-vivo female reproductive tract integration in a three dimensional (3D) microphysiologic system.

Abstract: The present invention relates generally to a three-dimensional cell and tissue culture system for the female reproductive tract. In particular provided herein the system includes individual female reproductive cultures in a dynamic microfluidic setting or integrated using a microfluidic microphysiologic system. In some embodiments, the present invention provides ex-vivo female reproductive tract integration in a three dimensional (3D) microphysiologic system.

Abstract: The present invention relates generally to a three-dimensional cell and tissue culture system for the female reproductive tract. In particular provided herein the system includes individual female reproductive cultures in a dynamic microfluidic setting or integrated using a microfluidic microphysiologic system. In some embodiments, the present invention provides ex-vivo female reproductive tract integration in a three dimensional (3D) microphysiologic system.

Abstract: The present invention relates generally to a three-dimensional cell and tissue culture system for the female reproductive tract. In particular provided herein the system includes individual female reproductive cultures in a dynamic microfluidic setting or integrated using a microfluidic microphysiologic system. In some embodiments, the present invention provides ex-vivo female reproductive tract integration in a three dimensional (3D) microphysiologic system.